Achieving Hepatitis C Micro-Elimination in a High-Burden Province of Thailand: The Phetchabun Model
Authors:
- Wijitra PhaengkhaWPWijitra Phaengkha
- Pornjarim NilyanimitPNPornjarim Nilyanimit
- Nungruthai SuntronwongNSNungruthai Suntronwong
- Jiratchaya PuenpaJPJiratchaya Puenpa
- Duong Hoang Huy LeDLDuong Hoang Huy Le
- Saranya NgamnimitSNSaranya Ngamnimit
- Pattama JanpathipPJPattama Janpathip
- Lapasrada KamputLKLapasrada Kamput
- Kawin ThongnoiKTKawin Thongnoi
- Wanalee ToomtaWTWanalee Toomta
- Phatcha WohanklongPWPhatcha Wohanklong
- Jarunlak SaokeawJSJarunlak Saokeaw
Open Access
- 1 August 2026
- journal article
- research article
- Published by MDPI AG in Tropical Medicine and Infectious Disease
- Vol. 11 (8) , 215
Abstract
The World Health Organization targets hepatitis C virus (HCV) elimination as a public-health threat by 2030. Phetchabun province, in lower northern Thailand, has historically reported one of the country’s highest HCV seroprevalence rates. We describe a province-wide, decentralized test-to-treat micro-elimination program implemented within Thailand’s universal health-coverage system. Adults aged 35–64 years (2020–2024) and individuals born before 1992 (late 2023) across all 11 districts were screened using fingerstick anti-HCV rapid diagnostic tests at sub-district health-promoting hospitals. Reactive participants underwent confirmatory HCV-RNA testing at three regional nodes. Eligible patients received pangenotypic sofosbuvir/velpatasvir for 12 weeks, with ribavirin added for cirrhosis. Sustained virological response at 12 weeks post-treatment (SVR12) was the primary outcome. Of 400,567 targeted individuals, 389,547 (97.3%) were screened; 18,340 (4.71%) were anti-HCV reactive. Confirmatory HCV-RNA testing was completed in 14,845 (80.9%), of whom 10,996 (74.1%) had active infection. Of 8961 treatment-eligible patients, 8842 (98.7%) received DAA therapy. Among 6719 evaluable for SVR12, 6474 (96.4%) achieved cure. This simplified, domestically financed, decentralized test-to-treat model achieved WHO-target-level diagnosis, treatment, and cure rates at provincial scale, offering a scalable framework for HCV micro-elimination in low- and middle-income countries.Keywords
Funding Information
- Health Systems Research Institute (HSRI No. 69-013)
- National Research Council of Thailand (RES_64_058_30_020)
- Chulalongkorn University (RA-MF-28/69)
- The Center of Excellence in Clinical Virology of Chulalongkorn University (-)
- King Chulalongkorn Memorial Hospital (-)
- the MK Restaurant Group, Aunt Thongkham Foundation (-)
- the Education and Public Welfare Foundation (-)
- the Second Century Fund (C2F) fellowship of Chulalongkorn University (-)
This publication has 53 references indexed in Scilit:
- Changhua Integrated Program to Stop HCV Infection (CHIPS–C): A county-wide model for integrated HCV elimination in TaiwanJournal of the Formosan Medical Association, 2025
- Micro-elimination of hepatitis C virus infection in the rural and remote areas of Taiwan – A multi-center collaborative care modelJournal of Microbiology, Immunology and Infection, 2023
- Sofosbuvir/Velpatasvir for Hepatitis C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in TaiwanInfectious Diseases and Therapy, 2021
- Reduced incidence of hepatitis C in 9 villages in rural Egypt: Progress towards national elimination goalsJournal of Hepatology, 2021
- EASL recommendations on treatment of hepatitis C: Final update of the series☆Journal of Hepatology, 2020
- Toward microelimination of hepatitis C and HIV coinfection in NHS Tayside, Scotland: Real‐world outcomesHealth Science Reports, 2020
- Rwanda launches a 5-year national hepatitis C elimination plan: A landmark in sub-Saharan AfricaJournal of Hepatology, 2019
- Micro-elimination – A path to global elimination of hepatitis CJournal of Hepatology, 2017
- External validation of FIB-4: Diagnostic accuracy is limited in elderly populationsHepatology, 2007
- Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfectionHepatology, 2006